Soluble interleukin-2 receptors in patients with advanced colorectal carcinoma

International Journal of Biological Markers

Volumn 11, Issue 1, 1996, Pages 6-11

  Pavlidis, N ^a   Nicolaides, C ^a   Bairaktari, E ^b   Kalef Ezra, J ^a   Athanassiadis, A ^c   Seferiadis, C ^b   Fountzilas, G ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

CA 19 9; CEA; Colorectal cancer; Soluble interleukin 2 receptors; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; INTERLEUKIN 2 RECEPTOR; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVAL TIME;

EID: 0029876970     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089601100102     Document Type: Article

References (35)

1. National Institute of Health. Annual cancer statistics review, including cancer trends: 1950-1985. 88th ed. Bethesda MD. National Institute of Health, 1988.
2. Koprowski H, Herlyn M, Steplewize Z, et al. Specific antigen in serum of patients with colon cancer. Science 1981; 212: 53-5.
3. Bhargava AK, Petrelli NJ, Kavna A, et al. Circulating CA 195 in colorectal cancer. J Tumor Marker Oncol 1987; 2: 319-27.
4. Heptner G, Domschke A, Domschke B. Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnosis of gastrointestinal malignancies. Scand J Gastroenterol 1986; 24: 745-50.
5. Holmgren J, Lindholm L, Pusson B, et al. Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Br Med J 1989; 288: 1479-82.
6. Wanebo HJ, Rao B, Pinsky CM, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 229: 448-51.
7. Minton JP, Hoehn JL, Gerber DM, et al. Results of a 400 patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55: 1284-90.
8. Symons JA, Wood NC, Di Giovine FS, Duff GW. Soluble interleukin-2 receptor in rheumatoid arthritis. J Immunol 1988; 141: 2612-8.
9. Keicho N, Kitamura K, Takaku F, Yotsumoto H. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest 1990; 98: 1125-9.
10. Brown AE, Rieder KT, Wehster HK. Prolonged elevation of soluble interleukin-2 receptors in tuberculosis. Am Rev Respir Dis 1989; 139: 1036-8.
11. Marino P, Cugno M, Preatoni A, et al. Increased levels soluble interleukin-2 receptors in serum of cancer patients. Br J Cancer 1990; 61: 434-5.
12. Roodman ST, Miller LW, Tsai CHC. Role of interleukin-2 receptors in immunologic monitoring following cardiac transplantation. Transplantation 1988; 45: 1050-6.
13. Honda M, Kitamura K, Matsuda K, Yokota Y, Yamamoto N, Mitsuyask R, et al. Soluble IL-2 receptors in AIDS. J Immunol 1989; 142: 4248-55.
14. Pavlidis N, Manoussakis MN, Germanidis GS, Moutsopoulos HM. Serum soluble interleukin-2 receptors in B-cell lymphoproliferative malignancies. Med Fed Oncol 1992; 20: 26-31.
15. Pavlidis N, Kalef-Ezra J, Bourantas LC, Lambrou A, Mavridis A. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia. Int J Biol Markers 1993; 8: 14-20.
16. Pavlidis N, Bairaktari E, Kalef-Ezra J, Nicolaides C, Seferiadis C, Fountzilas G. Serum soluble interleukin-2 receptor in epithelial ovarian cancer paitents. Int J Biol Markers 1995; 10: 75-80.
17. Marino P, Cugno M, Preatoni A, et al. Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer. Br J Cancer 1990; 61: 434-5.
18. Rovelli F, Lissoni P, Crispino S, Barni S, Fumagalli G, Paolorossi P, et al. Increased level of soluble interleukin-2 receptor in advanced solid tumors. Tumori 1988; 74: 633-7.
19. Duan ZF. Soluble interleukin-2 receptor in patients with esophageal carcinoma. Chung-Hua-Chung-Liu-Tsa-Chih 1993; 15: 17-9.
20. Murakami S, Satomi A, Ishida K, Murai H, Matsuki M, Hashimoto T. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer. Cancer 1994; 74: 2745-8.
21. Matthews DE, Farewell VT. Using and understanding medical statistics. Basel: S Karger, 1985.
22. Pizzolo G, Chilosi M, Vinante F, et al. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br J Cancer 1987; 55: 427-8.
23. Marcon L, Rubin LA, Kurman CC, et al. Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: Correlation with clinical status during chemotherapy. Ann Intern Med 1988; 109: 274-9.
24. Chilosi M, Pizzolo G, Semenzato G, Getto GL. Detection of a soluble form of the receptor for interleukin-2 in the serum of patients with hairy cell leukemia. Int J Biol Markers 1986; 1: 101-6.
25. Greene WC, Leonard WJ, Depper JM, Nelson DL, Waldmann TA. The human interleukin-2 receptor: normal and abnormal expression in T-cells and in leukemias induced by the human T-lymphocytic retroviruses. Ann Intern Med 1986; 105: 560-72.
26. Murakami S, Satomi A, Ishida K, Murai H, Okamura Y. Serum soluble interleukin-2 receptor in colorectal cancer. Acta Oncol 1994; 33: 19-21.
27. Tisi E, Lissoni P, Angeli M, et al. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer 1992; 69: 2458-62.
28. O'Garra A. Interleukins and the immune system: 1 Lancet 1989; i: 943-7.
29. Smith K.A. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169-76.
30. Malkovsky M, Sondel PM. Interleukin-2 and its receptor: structure, function and therapeutic potential. Blood Rev 1987; 1: 254-66.
31. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin-2 receptors are released by activated lymphocytes in vitro. J Immunol 1985; 135: 3172-7.
32. Rubin LA, Jay G, Nelson DL. The released interleukin-2 receptor binds interleukin-2 efficiently. J Immunol 1986; 137: 3841-5.
33. Gambacorti-Passerini C, Rovelli F, Ghezzi R, Traversari C, Belli F, Parmiani G. Serum CD25 levels in patients treated with recombinant interleukin 2 and lymphokine activated killers. Correlation with in vivo immune activation and induction of an immunosuppressive activity. J Immunol Res 1990; 2: 19.
34. Gambacorti C. Serum CD25 levels in cancer patients. Blood 1993; 82 (1): 326-30.
35. Klein B, Lurie H, Rakowsky E, Schechter J, Levin I, Klein T. The biological significance of soluble interleukin-2 and soluble interleukin-2 receptors in breast cancer patients. Proceed Amer Soc Clin Oncology 1993; 12: 96-185.